Helus Pharma Inc. (HELP) Stock Price, Quote & News

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology

Sector: Healthcare

Phone: 908-764-8385

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

Ridethesqueeze Jun. 29 at 1:19 PM

$HELP so did they use any of the $100M ATM?

0 · Reply

focafoca99 Jun. 29 at 11:59 AM

$HELP shared a $50 million underwritten offering to fund its Phase 3 HLP003 trial and reported FY 2026 results.

0 · Reply

LewisDaKat Jun. 29 at 10:00 AM

$HELP Expected earnings - Cybin Inc. https://marketwirenews.com/stock/help/news/expected-earnings-cybin-inc--5790475314595511.html?utm_source=stocktwits

0 · Reply

Buckwacker Jun. 28 at 9:34 AM

$HELP My wife telling me stop throwing good money after bad Me showing her it went up a buck

1 · Reply

EventHorizon8 Jun. 28 at 1:33 AM

Helus is set to follow the path of Definium but imagine another possibility. What if Helus and Definium merge and take on big pharma directly with two best in their class treatments for depression combined with Helus’s duteration tech. It would be lethal to big pharma and create a money printing press for investors. Think about it . $DFTX $HELP

1 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

3 · Reply

firetypecracker Jun. 27 at 8:24 PM

$HELP GREAT NEWS: Psychedelic Treatments Are on The Verge of FDA Approval. Why Texas is Pushing For Them... Psychedelic treatments are moving closer to federal approval, with the U.S. Food and Drug Administration taking steps to fast-track several compounds under review. The agency recently said three companies will receive National Priority Vouchers to speed their psychedelic drugs through the approval process. These include two psilocybin compounds for treatment-resistant depression and major depressive disorder, and methylone, a drug similar to MDMA, for post-traumatic stress disorder. Each previously received Breakthrough Therapy designation (Cybn:$HELP has received BTD), which the FDA awards to therapies for serious conditions that demonstrate a substantial improvement over currently available therapies. That announcement came one week after President Donald Trump signed a psychedelics executive order. https://www.houstonpublicmedia.org/articles/news/health-science/2026/05/05/550958/

0 · Reply

StockScanners Jun. 27 at 6:09 PM

$HELP ran to 6.60, lets go team

0 · Reply

cambruck7 Jun. 27 at 12:28 PM

$HELP

0 · Reply

QuietlyAccumulating Jun. 27 at 12:57 AM

$CMPS $HELP These will be Huge for PTSD (Post Trump Stress Disorder).

3 · Reply

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Jun 29, 2026, 7:00 AM EDT - 2 hours ago

Cybin Annual report: Q4 2026

Jun 25, 2026, 9:27 AM EDT - 3 days ago

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

2026-06-24T10:35:20.000Z - 5 days ago

Helus Pharma prices 10.31M common shares at $4.85 in public offering

2026-06-24T10:05:22.000Z - 5 days ago

Helus Pharma says enrollment in APPROACH Phase 3 trial ‘progressing as planned’

Jun 24, 2026, 6:01 AM EDT - 5 days ago

Helus Pharma™ Announces US$50 Million Underwritten Offering

Jun 24, 2026, 6:00 AM EDT - 5 days ago

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Jun 15, 2026, 7:00 AM EDT - 14 days ago

Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 11, 2026, 7:30 AM EDT - 18 days ago

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

Jun 4, 2026, 2:35 PM EDT - 24 days ago

Cybin Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 4 weeks ago

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Apr 30, 2026, 7:17 PM EDT - 2 months ago

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 30, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Apr 28, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 23, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 20, 2026, 2:05 PM EDT - 2 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

2026-04-20T14:47:00.000Z - 2 months ago

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

2026-04-20T12:41:24.000Z - 2 months ago

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

Apr 20, 2026, 8:15 AM EDT - 2 months ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 6:43 AM EDT - 2 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

2026-04-16T11:38:27.000Z - 2 months ago

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

BMY

Apr 16, 2026, 7:30 AM EDT - 2 months ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

2026-04-13T09:50:28.000Z - 2 months ago

Helus Pharma initiated with a Buy at TD Cowen

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Cybin Slides: Corporate presentation

2026-03-12T11:46:37.000Z - 3 months ago

Helus Pharma appoints Conwell as Chief People Officer

ACRS

Mar 12, 2026, 7:30 AM EDT - 3 months ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

2026-03-05T13:10:05.000Z - 4 months ago

Helus Pharma announces results in Phase 2 signal detection study of HLP004

Mar 5, 2026, 7:30 AM EST - 4 months ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Press release: Study result

Mar 5, 2026, 7:30 AM EST - 4 months ago

Cybin Slides: Study result

2026-02-24T13:04:49.000Z - 4 months ago

Helus Pharma appoints Freda Lewis-Hall to Board, Chair of Advisory Committee

PFE

Feb 24, 2026, 7:45 AM EST - 4 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 17, 2026, 7:30 AM EST - 4 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 13, 2026, 12:30 PM EST - 4 months ago

Cybin Earnings release: Q3 2026

Feb 13, 2026, 7:31 AM EST - 4 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Dec 30, 2025, 3:33 PM EST - 6 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 19, 2025, 7:00 AM EST - 6 months ago

Cybin Registration statement: Registration Filing

Dec 18, 2025, 12:29 PM EST - 6 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Nov 17, 2025, 7:30 AM EST - 8 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 8 months ago

Cybin Earnings release: Q2 2026

Nov 13, 2025, 7:20 AM EST - 8 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 8 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:30 PM EST - 8 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 2:00 PM EST - 8 months ago

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 7:30 AM EST - 8 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 8 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 8 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 8 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 9 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 17, 2025, 9:20 AM EDT - 10 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 8:00 AM EDT - 10 months ago

Cybin Registration statement: Registration Filing

Sep 11, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 11:00 AM EDT - 10 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 10 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 5, 2025, 10:20 AM EDT - 10 months ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 11 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 10:00 AM EDT - 11 months ago

Cybin Transcript: AGM 2025

Aug 13, 2025, 5:30 PM EDT - 11 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Cybin Earnings release: Q1 2026

Aug 12, 2025, 2:30 PM EDT - 11 months ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Cybin Registration statement: Registration Filing

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 1 year ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Earnings release: Q4 2025

Jul 1, 2025, 12:00 AM EDT - 1 year ago

Cybin Annual report: Q4 2025

Jun 30, 2025, 10:03 PM EDT - 1 year ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 1 year ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 1 year ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Ridethesqueeze Jun. 29 at 1:19 PM

$HELP so did they use any of the $100M ATM?

0 · Reply

focafoca99 Jun. 29 at 11:59 AM

$HELP shared a $50 million underwritten offering to fund its Phase 3 HLP003 trial and reported FY 2026 results.

0 · Reply

LewisDaKat Jun. 29 at 10:00 AM

$HELP Expected earnings - Cybin Inc. https://marketwirenews.com/stock/help/news/expected-earnings-cybin-inc--5790475314595511.html?utm_source=stocktwits

0 · Reply

Buckwacker Jun. 28 at 9:34 AM

$HELP My wife telling me stop throwing good money after bad Me showing her it went up a buck

1 · Reply

EventHorizon8 Jun. 28 at 1:33 AM

1 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

3 · Reply

firetypecracker Jun. 27 at 8:24 PM

0 · Reply

StockScanners Jun. 27 at 6:09 PM

$HELP ran to 6.60, lets go team

0 · Reply

cambruck7 Jun. 27 at 12:28 PM

$HELP

0 · Reply

QuietlyAccumulating Jun. 27 at 12:57 AM

$CMPS $HELP These will be Huge for PTSD (Post Trump Stress Disorder).

3 · Reply

BelieveinthePK Jun. 27 at 12:43 AM

$HELP if HELP were to match DFTX market cap, share price would be ~$97.

0 · Reply

cambruck7 Jun. 26 at 9:50 PM

$HELP

0 · Reply

Buccabrian Jun. 26 at 9:03 PM

$HELP $DFTX $CMPS $GHRS

0 · Reply

MichaelNaussCMT Jun. 26 at 9:00 PM

$CMPS $DFTX $GHRS $HELP low market caps and under performance happens for a reason. The market is smart.

3 · Reply

Sowa5000 Jun. 26 at 7:37 PM

$HELP this is a winner 🏆 Breakthrough status, low market cap compared to competitors, peak market sales in $2-$5B..just need to get passed the finish line..like the space $DFTX $CMPS $GHRS

2 · Reply

Olivia_Strickland Jun. 26 at 7:27 PM

$HELP grinding up 7.4% to 6.46 on solid tape, popped off the 6.02 close. these breakouts either keep extending or fade back into the range once buyers tire. parked watching for now, no read on what's driving it yet. anyone catching wind of a catalyst? this is what my scanner flagged: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=help-bk-up-scanner&utm_term=scanner&s=HELP

2 · Reply

brunoq14 Jun. 26 at 6:48 PM

$HELP Hard to believe that this was visiting its 52 week low around 3.76 just a couple of weeks ago.

1 · Reply

Marcelline Jun. 26 at 6:43 PM

$HELP still has gas in the tank

0 · Reply

BigBoyTroy Jun. 26 at 5:42 PM

$HELP resistance levels $6.60 $6.90–7.00 resistance and likely profit-taking area. $7.40–7.60 – Next major breakout zone if volume stays strong. A clean break above $6.60 with strong volume could open the door to a move toward $6.90–7.00. Looks like we need volume all the top gainers taking it away for now

0 · Reply

BigBoyTroy Jun. 26 at 5:23 PM

$HELP I'm liking this ticker to swing looking for dips before entering Free discord link in my stoctwits Profile my bullish 🐂 peeps

0 · Reply

Buckwacker Jun. 26 at 5:13 PM

$HELP any new bull watcher, take few minutes and look at the website/pipeline I’ve been holding bag for long time, lower average few times and still underwater But I’ve never sold a share…. 🙏 Bottom line it’ll help a whole buncha vets

1 · Reply

Dutchholdem Jun. 26 at 4:53 PM

$HELP bought this may 20th, only small position eying q4. What has happened last week? Did not really check due to small position but see I am 50% up all of the sudden

1 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	864,772
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A